董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Richard S. Levy | 男 | Director | 61 | 未披露 | 未持股 | 2018-10-03 |
| Victor Perlroth | 男 | Chief Executive Officer, President and Chairman of the Board | 45 | 249.92万美元 | 未持股 | 2018-10-03 |
| Felix J. Baker | 男 | Director | 49 | 9.28万美元 | 1741.88 | 2018-10-03 |
| Robert A. Profusek | 男 | Director | 68 | 17.93万美元 | 16.84 | 2018-10-03 |
| Richard S. Levy | 男 | Director | 61 | 14.28万美元 | 15.94 | 2018-10-03 |
| Bassil I. Dahiyat | 男 | Director | 47 | 14.78万美元 | 13.34 | 2018-10-03 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Victor Perlroth | 男 | Chief Executive Officer, President and Chairman of the Board | 45 | 249.92万美元 | 未持股 | 2018-10-03 |
| Jason Ehrlich | 男 | Chief Medical Officer and Chief Development Officer | 42 | 305.62万美元 | 未持股 | 2018-10-03 |
| John A. Borgeson | 男 | Senior Vice President and Chief Financial Officer | 57 | 161.59万美元 | 113.75 | 2018-10-03 |
| Hong Liang | -- | Senior Vice President, Discovery Medicine | 46 | 32.19万美元 | 未持股 | 2018-10-03 |
董事简历
中英对照 | 中文 | 英文- Richard S. Levy
-
暂无中文简介
Richard S. Levy, M.D. has been a member of our Board of Directors since August 2016. Currently, Dr. Levy is a part-time Senior Advisor for Baker Bros. Advisors, L.P., a firm that primarily manages long-term investment funds focused on publicly traded life sciences companies, and as a part-time Advisor for Incyte Corporation, a publicly-held biopharmaceutical company. Dr. Levy also serves on the board of directors of Aquinox Pharmaceuticals, Inc., a publicly-held pharmaceutical company, and Gliknik Inc., a privately-held biotechnology company. Previously, Dr. Levy served as Executive Vice President and Chief Drug Development Officer at Incyte from January 2009 until his retirement in April 2016 and as Senior Vice President of Drug Development from August 2003 to January 2009. Prior to joining Incyte, Dr. Levy served as Vice President, Biologic Therapies, at Celgene Corporation, a publicly-held biopharmaceutical company, from 2002 to 2003. From 1997 to 2002 Dr. Levy served in various executive positions with DuPont Pharmaceuticals Company, first as Vice President, Regulatory Affairs and Pharmacovigilence, and thereafter as Vice President, Medical and Commercial Strategy. Dr. Levy served at Novartis, and its predecessor company Sandoz, from 1991 to 1997 in positions of increasing responsibility in clinical research and regulatory affairs. Prior to joining the pharmaceutical industry, Dr. Levy served as an Assistant Professor of Medicine at the UCLA School of Medicine. Dr. Levy is Board Certified in Internal Medicine and Gastroenterology and received his A.B. in Biology from Brown University, his M.D. from the University of Pennsylvania School of Medicine, and completed his training in Internal Medicine at the Hospital of the University of Pennsylvania and a fellowship in Gastroenterology and Hepatology at UCLA. -
暂无中文简介
- Richard S. Levy, M.D. has been a member of our Board of Directors since August 2016. Currently, Dr. Levy is a part-time Senior Advisor for Baker Bros. Advisors, L.P., a firm that primarily manages long-term investment funds focused on publicly traded life sciences companies, and as a part-time Advisor for Incyte Corporation, a publicly-held biopharmaceutical company. Dr. Levy also serves on the board of directors of Aquinox Pharmaceuticals, Inc., a publicly-held pharmaceutical company, and Gliknik Inc., a privately-held biotechnology company. Previously, Dr. Levy served as Executive Vice President and Chief Drug Development Officer at Incyte from January 2009 until his retirement in April 2016 and as Senior Vice President of Drug Development from August 2003 to January 2009. Prior to joining Incyte, Dr. Levy served as Vice President, Biologic Therapies, at Celgene Corporation, a publicly-held biopharmaceutical company, from 2002 to 2003. From 1997 to 2002 Dr. Levy served in various executive positions with DuPont Pharmaceuticals Company, first as Vice President, Regulatory Affairs and Pharmacovigilence, and thereafter as Vice President, Medical and Commercial Strategy. Dr. Levy served at Novartis, and its predecessor company Sandoz, from 1991 to 1997 in positions of increasing responsibility in clinical research and regulatory affairs. Prior to joining the pharmaceutical industry, Dr. Levy served as an Assistant Professor of Medicine at the UCLA School of Medicine. Dr. Levy is Board Certified in Internal Medicine and Gastroenterology and received his A.B. in Biology from Brown University, his M.D. from the University of Pennsylvania School of Medicine, and completed his training in Internal Medicine at the Hospital of the University of Pennsylvania and a fellowship in Gastroenterology and Hepatology at UCLA.
- Victor Perlroth
-
Victor Perlroth于2009年共同创立了Kodiak Sciences，是我们的董事长兼首席执行官。此前，Perlroth博士曾担任MPM Capital（一家专门的梦百合风险资本投资公司）的风险合伙人和常驻企业家。2003年，Perlroth博士共同创立了Avidia Inc.，该公司是一家生物制药药物发现和开发公司，后被安进公司收购，他在该公司担任总经理和企业发展Vice President。在担任这一职务期间，他在不同时期对公司和研究与开发活动负有广泛的管理责任。此前，他曾任职Guzik Technical Enterprises公司（硬盘驱动器行业测试设备的行业领先供应商），在那里他曾担任首席运营官。Perlroth博士在斯坦福大学（Stanford University）获得M.D.和M.B.A.学位，并在普林斯顿大学（Princeton University）以优异成绩获得分子生物学学士学位。
Victor Perlroth co-founded Kodiak Sciences in 2009 and is our Chairman and Chief Executive Officer. Previously, Dr. Perlroth served as Venture Partner and then Entrepreneur in Residence at MPM Capital, a dedicated healthcare venture capital investment firm. In 2003 Dr. Perlroth co-founded Avidia Inc., a biopharmaceuticals drug discovery and development company which was acquired by Amgen Inc., where he served as General Manager and Vice President of Corporate Development. In this role, at various times he had broad management responsibility across both corporate and research and development activities. Previously, Dr. Perlroth worked at Guzik Technical Enterprises, an industry-leading provider of test equipment to the hard disk drive industry, where he was Chief Operating Officer. Dr. Perlroth earned his M.D. and M.B.A. degrees from Stanford University and an A.B. in Molecular Biology summa cum laude from Princeton University. - Victor Perlroth于2009年共同创立了Kodiak Sciences，是我们的董事长兼首席执行官。此前，Perlroth博士曾担任MPM Capital（一家专门的梦百合风险资本投资公司）的风险合伙人和常驻企业家。2003年，Perlroth博士共同创立了Avidia Inc.，该公司是一家生物制药药物发现和开发公司，后被安进公司收购，他在该公司担任总经理和企业发展Vice President。在担任这一职务期间，他在不同时期对公司和研究与开发活动负有广泛的管理责任。此前，他曾任职Guzik Technical Enterprises公司（硬盘驱动器行业测试设备的行业领先供应商），在那里他曾担任首席运营官。Perlroth博士在斯坦福大学（Stanford University）获得M.D.和M.B.A.学位，并在普林斯顿大学（Princeton University）以优异成绩获得分子生物学学士学位。
- Victor Perlroth co-founded Kodiak Sciences in 2009 and is our Chairman and Chief Executive Officer. Previously, Dr. Perlroth served as Venture Partner and then Entrepreneur in Residence at MPM Capital, a dedicated healthcare venture capital investment firm. In 2003 Dr. Perlroth co-founded Avidia Inc., a biopharmaceuticals drug discovery and development company which was acquired by Amgen Inc., where he served as General Manager and Vice President of Corporate Development. In this role, at various times he had broad management responsibility across both corporate and research and development activities. Previously, Dr. Perlroth worked at Guzik Technical Enterprises, an industry-leading provider of test equipment to the hard disk drive industry, where he was Chief Operating Officer. Dr. Perlroth earned his M.D. and M.B.A. degrees from Stanford University and an A.B. in Molecular Biology summa cum laude from Princeton University.
- Felix J. Baker
-
Felix J. Baker，2004年4月以来担任公司的董事，目前担任董事会主席。之前，Baker博士2000年10月起，也是Private Synageva的董事，一直到合并为止，也从2003年起，担任Private Synageva的董事会主席，一直到合并为止。Baker博士和他的兄弟Julian Baker是Baker Bros. Advisors, LP. Dr. Baker的联合管理成员，1994年开始了他们基金管理职业生涯，那时他们和Tisch家族联合建立了一家生物技术投资公司。2000年，他们建立了Baker Bros。 咨询公司。Baker博士拥有斯坦福大学免疫学学士学位和博士学位，在那里，他也完成了2年的医学院课程。除了公司职位之外，Baker博士是Genomic Health和Seattle Genetics的董事，两家都是生物技术公司。Baker博士之前是AnorMED ， Ardea Bioscience， Conjuchem和Neurogen 的董事，在他的任期里，这些公司都是上市公司。
Felix J. Baker,has served as Lead Independent Director (as defined below) and on Board of Directors since October 2015. Dr. Baker is a Managing Member of Baker Bros. Advisors, a biotechnology-focused investment adviser to fund partnerships whose investors are primarily endowments and foundations, which Dr. Baker founded, together with his brother Julian Baker, in 2000. Dr. Baker holds a B.S. and a Ph.D. in Immunology from Stanford University, where he also completed two years of medical school. He serves on the boards of Kodiak Sciences, Inc., IGM Biosciences, Inc. Kymera Therapeutics, Inc., and Bicycle Therapeutics plc. - Felix J. Baker，2004年4月以来担任公司的董事，目前担任董事会主席。之前，Baker博士2000年10月起，也是Private Synageva的董事，一直到合并为止，也从2003年起，担任Private Synageva的董事会主席，一直到合并为止。Baker博士和他的兄弟Julian Baker是Baker Bros. Advisors, LP. Dr. Baker的联合管理成员，1994年开始了他们基金管理职业生涯，那时他们和Tisch家族联合建立了一家生物技术投资公司。2000年，他们建立了Baker Bros。 咨询公司。Baker博士拥有斯坦福大学免疫学学士学位和博士学位，在那里，他也完成了2年的医学院课程。除了公司职位之外，Baker博士是Genomic Health和Seattle Genetics的董事，两家都是生物技术公司。Baker博士之前是AnorMED ， Ardea Bioscience， Conjuchem和Neurogen 的董事，在他的任期里，这些公司都是上市公司。
- Felix J. Baker,has served as Lead Independent Director (as defined below) and on Board of Directors since October 2015. Dr. Baker is a Managing Member of Baker Bros. Advisors, a biotechnology-focused investment adviser to fund partnerships whose investors are primarily endowments and foundations, which Dr. Baker founded, together with his brother Julian Baker, in 2000. Dr. Baker holds a B.S. and a Ph.D. in Immunology from Stanford University, where he also completed two years of medical school. He serves on the boards of Kodiak Sciences, Inc., IGM Biosciences, Inc. Kymera Therapeutics, Inc., and Bicycle Therapeutics plc.
- Robert A. Profusek
-
Robert A. Profusek是琼斯天并购的负责人，他在1975年加入这家全球性律师事务所。他也是瓦莱罗能源公司的首席董事，并是该公司的薪酬委员会及提名委员及治理委员会委员。此前，他曾担任另外两个纽约证券交易所上市公司的董事。
Robert A. Profusek,is a partner with Jones Day, a leading global law firm, where he serves as the Chair of the Global Mergers and Acquisitions practice. Since joining Jones Day in 1975, Mr. Profusek has been recognized as one of the world's leading mergers and acquisitions and corporate governance lawyers. He has worked on hundreds of mergers, acquisitions and buyouts and has advised many boards and director committees on sensitive governance matters.Since 2005, Mr. Profusek has been a member of the board of directors of Valero Energy Corporation (NYSE: VLO), the largest independent petroleum refiner in the world and the world's second largest renewable fuels producer, currently serving as Lead Independent Director and as a member of the Human Resources and Compensation Committee. Mr. Profusek is also a member of the board of directors of Kodiak Sciences, Inc., (NASDAQ: KOD), a biopharmaceutical company specializing in therapeutics to treat chronic, high-prevalence ophthalmic diseases, and currently serves as Lead Independent Director, Chair of the Nominating and Corporate Governance Committee and as a member of the Compensation Committee. He previously served as a director of two other publicly traded companies that were acquired. - Robert A. Profusek是琼斯天并购的负责人，他在1975年加入这家全球性律师事务所。他也是瓦莱罗能源公司的首席董事，并是该公司的薪酬委员会及提名委员及治理委员会委员。此前，他曾担任另外两个纽约证券交易所上市公司的董事。
- Robert A. Profusek,is a partner with Jones Day, a leading global law firm, where he serves as the Chair of the Global Mergers and Acquisitions practice. Since joining Jones Day in 1975, Mr. Profusek has been recognized as one of the world's leading mergers and acquisitions and corporate governance lawyers. He has worked on hundreds of mergers, acquisitions and buyouts and has advised many boards and director committees on sensitive governance matters.Since 2005, Mr. Profusek has been a member of the board of directors of Valero Energy Corporation (NYSE: VLO), the largest independent petroleum refiner in the world and the world's second largest renewable fuels producer, currently serving as Lead Independent Director and as a member of the Human Resources and Compensation Committee. Mr. Profusek is also a member of the board of directors of Kodiak Sciences, Inc., (NASDAQ: KOD), a biopharmaceutical company specializing in therapeutics to treat chronic, high-prevalence ophthalmic diseases, and currently serves as Lead Independent Director, Chair of the Nominating and Corporate Governance Committee and as a member of the Compensation Committee. He previously served as a director of two other publicly traded companies that were acquired.
- Richard S. Levy
-
2003年8月，Richard S. Levy加入公司，并担任药物开发的高级副总裁；2009年1月，开始担任执行副总裁兼首席药物开发和医疗官。加入Incyte之前，从2002年到2003年，他在 Celgene Corporation担任药物开发职位，负责临床研究和监管事务；从1997年到2002年，在 DuPont Pharmaceuticals Company任职；从1991年到1997年，在 Sandoz任职， Sandoz现在是Novartis的一部分。加入制药行业之前，他是加州大学洛杉矶分校医学院的医学助理教授。他是内科医学胃肠病学委员会成员，取得了布朗大学文科学士和宾夕法尼亚大学医学博士学位。
Richard S. Levy,has served on Board of Directors since March 2019. Dr. Levy served as a Senior Advisor at Baker Bros. Advisors LP ("Baker Brothers Advisors") from December 2016 to May 2019. Prior to that, Dr. Levy served as Executive Vice President and Chief Drug Development Officer at Incyte Corporation, a biopharmaceutical company, from January 2009 until June 2016, and as Senior Vice President of Drug Development from August 2003 to January 2009. Dr. Levy currently serves on the boards of directors of Madrigal Pharmaceuticals, Inc., Protara Therapeutics, Inc. (f/k/a ArTara Therapeutics, Inc.) and Kodiak Sciences, and previously served on the board of directors of Constellation Pharmaceuticals, Inc. and Aquinox Pharmaceuticals, Inc. Dr. Levy is Board Certified in Internal Medicine and Gastroenterology and holds an A.B. in Biology from Brown University and an M.D. from the University of Pennsylvania School of Medicine, and completed his training in Internal Medicine at the Hospital of the University of Pennsylvania and a fellowship in Gastroenterology and Hepatology at UCLA. - 2003年8月，Richard S. Levy加入公司，并担任药物开发的高级副总裁；2009年1月，开始担任执行副总裁兼首席药物开发和医疗官。加入Incyte之前，从2002年到2003年，他在 Celgene Corporation担任药物开发职位，负责临床研究和监管事务；从1997年到2002年，在 DuPont Pharmaceuticals Company任职；从1991年到1997年，在 Sandoz任职， Sandoz现在是Novartis的一部分。加入制药行业之前，他是加州大学洛杉矶分校医学院的医学助理教授。他是内科医学胃肠病学委员会成员，取得了布朗大学文科学士和宾夕法尼亚大学医学博士学位。
- Richard S. Levy,has served on Board of Directors since March 2019. Dr. Levy served as a Senior Advisor at Baker Bros. Advisors LP ("Baker Brothers Advisors") from December 2016 to May 2019. Prior to that, Dr. Levy served as Executive Vice President and Chief Drug Development Officer at Incyte Corporation, a biopharmaceutical company, from January 2009 until June 2016, and as Senior Vice President of Drug Development from August 2003 to January 2009. Dr. Levy currently serves on the boards of directors of Madrigal Pharmaceuticals, Inc., Protara Therapeutics, Inc. (f/k/a ArTara Therapeutics, Inc.) and Kodiak Sciences, and previously served on the board of directors of Constellation Pharmaceuticals, Inc. and Aquinox Pharmaceuticals, Inc. Dr. Levy is Board Certified in Internal Medicine and Gastroenterology and holds an A.B. in Biology from Brown University and an M.D. from the University of Pennsylvania School of Medicine, and completed his training in Internal Medicine at the Hospital of the University of Pennsylvania and a fellowship in Gastroenterology and Hepatology at UCLA.
- Bassil I. Dahiyat
-
Bassil I. Dahiyat，自2005年2月起担任总裁兼首席执行官，自1997年8月起担任董事会成员。Dahiyat博士于1997年与他人共同创立了Xencor，并于1997年至2003年担任首席执行官，并于2003年至2005年担任首席科学官。2005年，Dahiyat博士被世界经济论坛认定为技术先驱。此外，Dahiyat博士因其在蛋白质设计及其治疗应用开发方面的工作而被麻省理工学院技术评论杂志评为2003年百大年轻创新者之一，并获得了美国化学学会、控释学会和加州理工学院的奖项。Dahiyat博士拥有加州理工学院化学博士学位和约翰霍普金斯大学生物医学工程学士学位和M.S.E.学位。
Bassil I. Dahiyat,has served as President and Chief Executive Officer since February 2005 and as a member of Board of Directors since August 1997. Dr. Dahiyat co-founded Xencor in 1997 and, from 1997 to 2003 served as Chief Executive Officer and, from 2003 to 2005 served as Chief Scientific Officer. In 2005 Dr. Dahiyat was recognized as a technology pioneer by the World Economic Forum. Additionally, Dr. Dahiyat was named one of 2003's Top 100 Young Innovators by MIT's Technology Review magazine for his work on protein design and its development for therapeutic applications and has received awards from the American Chemical Society, the Controlled Release Society and the California Institute of Technology. Dr. Dahiyat holds a Ph.D. in Chemistry from the California Institute of Technology and B.S. and M.S.E. degrees in Biomedical Engineering from Johns Hopkins University. - Bassil I. Dahiyat，自2005年2月起担任总裁兼首席执行官，自1997年8月起担任董事会成员。Dahiyat博士于1997年与他人共同创立了Xencor，并于1997年至2003年担任首席执行官，并于2003年至2005年担任首席科学官。2005年，Dahiyat博士被世界经济论坛认定为技术先驱。此外，Dahiyat博士因其在蛋白质设计及其治疗应用开发方面的工作而被麻省理工学院技术评论杂志评为2003年百大年轻创新者之一，并获得了美国化学学会、控释学会和加州理工学院的奖项。Dahiyat博士拥有加州理工学院化学博士学位和约翰霍普金斯大学生物医学工程学士学位和M.S.E.学位。
- Bassil I. Dahiyat,has served as President and Chief Executive Officer since February 2005 and as a member of Board of Directors since August 1997. Dr. Dahiyat co-founded Xencor in 1997 and, from 1997 to 2003 served as Chief Executive Officer and, from 2003 to 2005 served as Chief Scientific Officer. In 2005 Dr. Dahiyat was recognized as a technology pioneer by the World Economic Forum. Additionally, Dr. Dahiyat was named one of 2003's Top 100 Young Innovators by MIT's Technology Review magazine for his work on protein design and its development for therapeutic applications and has received awards from the American Chemical Society, the Controlled Release Society and the California Institute of Technology. Dr. Dahiyat holds a Ph.D. in Chemistry from the California Institute of Technology and B.S. and M.S.E. degrees in Biomedical Engineering from Johns Hopkins University.
高管简历
中英对照 | 中文 | 英文- Victor Perlroth
Victor Perlroth于2009年共同创立了Kodiak Sciences，是我们的董事长兼首席执行官。此前，Perlroth博士曾担任MPM Capital（一家专门的梦百合风险资本投资公司）的风险合伙人和常驻企业家。2003年，Perlroth博士共同创立了Avidia Inc.，该公司是一家生物制药药物发现和开发公司，后被安进公司收购，他在该公司担任总经理和企业发展Vice President。在担任这一职务期间，他在不同时期对公司和研究与开发活动负有广泛的管理责任。此前，他曾任职Guzik Technical Enterprises公司（硬盘驱动器行业测试设备的行业领先供应商），在那里他曾担任首席运营官。Perlroth博士在斯坦福大学（Stanford University）获得M.D.和M.B.A.学位，并在普林斯顿大学（Princeton University）以优异成绩获得分子生物学学士学位。
Victor Perlroth co-founded Kodiak Sciences in 2009 and is our Chairman and Chief Executive Officer. Previously, Dr. Perlroth served as Venture Partner and then Entrepreneur in Residence at MPM Capital, a dedicated healthcare venture capital investment firm. In 2003 Dr. Perlroth co-founded Avidia Inc., a biopharmaceuticals drug discovery and development company which was acquired by Amgen Inc., where he served as General Manager and Vice President of Corporate Development. In this role, at various times he had broad management responsibility across both corporate and research and development activities. Previously, Dr. Perlroth worked at Guzik Technical Enterprises, an industry-leading provider of test equipment to the hard disk drive industry, where he was Chief Operating Officer. Dr. Perlroth earned his M.D. and M.B.A. degrees from Stanford University and an A.B. in Molecular Biology summa cum laude from Princeton University.- Victor Perlroth于2009年共同创立了Kodiak Sciences，是我们的董事长兼首席执行官。此前，Perlroth博士曾担任MPM Capital（一家专门的梦百合风险资本投资公司）的风险合伙人和常驻企业家。2003年，Perlroth博士共同创立了Avidia Inc.，该公司是一家生物制药药物发现和开发公司，后被安进公司收购，他在该公司担任总经理和企业发展Vice President。在担任这一职务期间，他在不同时期对公司和研究与开发活动负有广泛的管理责任。此前，他曾任职Guzik Technical Enterprises公司（硬盘驱动器行业测试设备的行业领先供应商），在那里他曾担任首席运营官。Perlroth博士在斯坦福大学（Stanford University）获得M.D.和M.B.A.学位，并在普林斯顿大学（Princeton University）以优异成绩获得分子生物学学士学位。
- Victor Perlroth co-founded Kodiak Sciences in 2009 and is our Chairman and Chief Executive Officer. Previously, Dr. Perlroth served as Venture Partner and then Entrepreneur in Residence at MPM Capital, a dedicated healthcare venture capital investment firm. In 2003 Dr. Perlroth co-founded Avidia Inc., a biopharmaceuticals drug discovery and development company which was acquired by Amgen Inc., where he served as General Manager and Vice President of Corporate Development. In this role, at various times he had broad management responsibility across both corporate and research and development activities. Previously, Dr. Perlroth worked at Guzik Technical Enterprises, an industry-leading provider of test equipment to the hard disk drive industry, where he was Chief Operating Officer. Dr. Perlroth earned his M.D. and M.B.A. degrees from Stanford University and an A.B. in Molecular Biology summa cum laude from Princeton University.
- Jason Ehrlich
Jason Ehrlich于2018年9月加入Kodiak，担任首席医疗官和首席开发官。眼科医生Ehrlich博士热衷于通过开发创新药物来改善视力受到威胁的眼病患者的预后。他因在眼科药物开发方面的领导能力和专业知识而获得国际认可。加入Kodiak之前，Ehrlich博士担任Genentech的临床眼科全球主管，该公司是Roche Group of Pharmaceutical Companies的成员。从2008年7月至2018年8月，Ehrlich博士作为糖尿病眼病Lucentis的首席临床医生，在Genentech和Roche承担了越来越大的责任，导致FDA咨询委员会一致投票这是FDA首次批准治疗糖尿病性黄斑水肿的眼内药物；随后，他倡导将Lucentis标签进一步扩展到所有形式的糖尿病性视网膜病变，从而获得了FDA的又一次批准。Ehrlich博士指导眼科药物输送公司Forsight Vision4被收购后整合到Genentech/Roche，包括监督Ranibizumab端口输送系统成功的II期研究。在他的工作中，Ehrlich博士参与或监督了众多的补充生物制剂许可申请以及FDA和欧洲卫生局的互动。他曾领导Lampalizumab公司的全球开发，包括Pivotal III期项目的设计和执行，该项目包括1800多名患者、275个站点和20多个国家。他还监督他的团队努力确保Lucentis在其预充式注射器中获得FDA批准，用于病理性近视引起的脉络膜新生血管，并成功过渡到RO6867461a视网膜血管疾病新型双特异性抗体的全球III期开发。Ehrlich博士在斯坦福大学医学院（Stanford University School of Medicine）完成眼科住院医师学位，通过美国国立卫生研究院（NIH）资助的医学科学家培训计划获得斯坦福大学（Stanford）的医学博士学位和博士学位，并在普林斯顿大学（Princeton University）以优异成绩获得分子生物学学士学位。
Jason Ehrlich joined Kodiak as our Chief Medical Officer and Chief Development Officer in September 2018. Dr. Ehrlich, an ophthalmologist, is passionate about improving outcomes for patients with vision-threatening eye diseases through the development of innovative medicines. He is internationally recognized for his leadership and expertise in ophthalmic drug development. Prior to joining Kodiak, Dr. Ehrlich served in an executive capacity as Global Head, Clinical Ophthalmology at Genentech, a member of the Roche Group of pharmaceutical companies. In roles of increasing responsibility at Genentech and Roche from July 2008 to August 2018 Dr. Ehrlich’s efforts as lead clinician for Lucentis in diabetic eye disease resulted in a unanimous FDA Advisory Committee vote and the first-ever FDA approval of an intraocular drug for diabetic macular edema; he then championed further expanding the Lucentis labeling into all forms of diabetic retinopathy, resulting in another first-ever FDA approval. Dr. Ehrlich guided the integration of the ophthalmic drug delivery company ForSIGHT VISION4 into Genentech/Roche after its acquisition, including oversight of the successful Phase II study of the ranibizumab Port Delivery System. In his work, Dr. Ehrlich has participated in or overseen numerous supplemental biologics license applications and both FDA and European health authority interactions. He led the global development of lampalizumab, including design and execution of the pivotal Phase III program that included over 1800 patients, over 275 sites, and more than 20 countries. He also oversaw his team’s effort to secure FDA approvals of Lucentis in its prefilled syringe and for choroidal neovascularization due to pathologic myopia, and the successful transition to global Phase III development of RO6867461 a novel bispecific antibody for retinal vascular disease. Dr. Ehrlich completed his Ophthalmology residency at Stanford University School of Medicine, earned his M.D. and Ph.D. degrees from Stanford through the NIH-funded Medical Scientist Training Program, and received his A.B. in Molecular Biology summa cum laude from Princeton University.- Jason Ehrlich于2018年9月加入Kodiak，担任首席医疗官和首席开发官。眼科医生Ehrlich博士热衷于通过开发创新药物来改善视力受到威胁的眼病患者的预后。他因在眼科药物开发方面的领导能力和专业知识而获得国际认可。加入Kodiak之前，Ehrlich博士担任Genentech的临床眼科全球主管，该公司是Roche Group of Pharmaceutical Companies的成员。从2008年7月至2018年8月，Ehrlich博士作为糖尿病眼病Lucentis的首席临床医生，在Genentech和Roche承担了越来越大的责任，导致FDA咨询委员会一致投票这是FDA首次批准治疗糖尿病性黄斑水肿的眼内药物；随后，他倡导将Lucentis标签进一步扩展到所有形式的糖尿病性视网膜病变，从而获得了FDA的又一次批准。Ehrlich博士指导眼科药物输送公司Forsight Vision4被收购后整合到Genentech/Roche，包括监督Ranibizumab端口输送系统成功的II期研究。在他的工作中，Ehrlich博士参与或监督了众多的补充生物制剂许可申请以及FDA和欧洲卫生局的互动。他曾领导Lampalizumab公司的全球开发，包括Pivotal III期项目的设计和执行，该项目包括1800多名患者、275个站点和20多个国家。他还监督他的团队努力确保Lucentis在其预充式注射器中获得FDA批准，用于病理性近视引起的脉络膜新生血管，并成功过渡到RO6867461a视网膜血管疾病新型双特异性抗体的全球III期开发。Ehrlich博士在斯坦福大学医学院（Stanford University School of Medicine）完成眼科住院医师学位，通过美国国立卫生研究院（NIH）资助的医学科学家培训计划获得斯坦福大学（Stanford）的医学博士学位和博士学位，并在普林斯顿大学（Princeton University）以优异成绩获得分子生物学学士学位。
- Jason Ehrlich joined Kodiak as our Chief Medical Officer and Chief Development Officer in September 2018. Dr. Ehrlich, an ophthalmologist, is passionate about improving outcomes for patients with vision-threatening eye diseases through the development of innovative medicines. He is internationally recognized for his leadership and expertise in ophthalmic drug development. Prior to joining Kodiak, Dr. Ehrlich served in an executive capacity as Global Head, Clinical Ophthalmology at Genentech, a member of the Roche Group of pharmaceutical companies. In roles of increasing responsibility at Genentech and Roche from July 2008 to August 2018 Dr. Ehrlich’s efforts as lead clinician for Lucentis in diabetic eye disease resulted in a unanimous FDA Advisory Committee vote and the first-ever FDA approval of an intraocular drug for diabetic macular edema; he then championed further expanding the Lucentis labeling into all forms of diabetic retinopathy, resulting in another first-ever FDA approval. Dr. Ehrlich guided the integration of the ophthalmic drug delivery company ForSIGHT VISION4 into Genentech/Roche after its acquisition, including oversight of the successful Phase II study of the ranibizumab Port Delivery System. In his work, Dr. Ehrlich has participated in or overseen numerous supplemental biologics license applications and both FDA and European health authority interactions. He led the global development of lampalizumab, including design and execution of the pivotal Phase III program that included over 1800 patients, over 275 sites, and more than 20 countries. He also oversaw his team’s effort to secure FDA approvals of Lucentis in its prefilled syringe and for choroidal neovascularization due to pathologic myopia, and the successful transition to global Phase III development of RO6867461 a novel bispecific antibody for retinal vascular disease. Dr. Ehrlich completed his Ophthalmology residency at Stanford University School of Medicine, earned his M.D. and Ph.D. degrees from Stanford through the NIH-funded Medical Scientist Training Program, and received his A.B. in Molecular Biology summa cum laude from Princeton University.
- John A. Borgeson
JohnA.Borgeson是我们的高级副总裁和首席财务官，自2016年1月以来一直担任该职位。从2013年1月到2015年12月，Borgeson先生领导多家私人生物技术公司的财务，包括Labrys Biologics，Inc.，该公司被Teva Pharmaceuticals收购。在此之前，Borgeson先生是辉瑞公司公司的财务Vice President，也是辉瑞公司全球财务和业务运营领导团队的成员。Borgeson先生在辉瑞公司（Pfizer）的职位包括辉瑞公司（Pfizer）的生物疗法和生物创新集团的财务主管以及负责美国和欧洲的公司税务主管。Borgeson先生的职业生涯始于担任安永会计师事务所（Ernst&Young）的审计师，是一名不活跃的注册会计师。他拥有R.I.T.的工商管理硕士学位，以及the University at Buffalo（S.U.N.Y.）的管理学院的本科学位。
John A. Borgeson is our Senior Vice President and Chief Financial Officer and has served in this position since January 2016.From January 2013 until December 2015 Mr. Borgeson led finance for a variety of private biotech companies, including Labrys Biologics, Inc., which was acquired by Teva Pharmaceuticals. Previously, Mr. Borgeson was a Vice President of Finance at Pfizer Inc. and a member of Pfizer's Global Finance and Business Operations Leadership Team. Mr. Borgeson's roles at Pfizer included finance head for Pfizer's biotherapeutics and bioinnovation group and corporate tax executive with responsibility for the United States and Europe. Mr. Borgeson started his career as an auditor with Ernst & Young and is a certified public accountant inactive. He has an M.B.A. from R.I.T. and an undergraduate degree from the School of Management at the University at Buffalo (S.U.N.Y.).- JohnA.Borgeson是我们的高级副总裁和首席财务官，自2016年1月以来一直担任该职位。从2013年1月到2015年12月，Borgeson先生领导多家私人生物技术公司的财务，包括Labrys Biologics，Inc.，该公司被Teva Pharmaceuticals收购。在此之前，Borgeson先生是辉瑞公司公司的财务Vice President，也是辉瑞公司全球财务和业务运营领导团队的成员。Borgeson先生在辉瑞公司（Pfizer）的职位包括辉瑞公司（Pfizer）的生物疗法和生物创新集团的财务主管以及负责美国和欧洲的公司税务主管。Borgeson先生的职业生涯始于担任安永会计师事务所（Ernst&Young）的审计师，是一名不活跃的注册会计师。他拥有R.I.T.的工商管理硕士学位，以及the University at Buffalo（S.U.N.Y.）的管理学院的本科学位。
- John A. Borgeson is our Senior Vice President and Chief Financial Officer and has served in this position since January 2016.From January 2013 until December 2015 Mr. Borgeson led finance for a variety of private biotech companies, including Labrys Biologics, Inc., which was acquired by Teva Pharmaceuticals. Previously, Mr. Borgeson was a Vice President of Finance at Pfizer Inc. and a member of Pfizer's Global Finance and Business Operations Leadership Team. Mr. Borgeson's roles at Pfizer included finance head for Pfizer's biotherapeutics and bioinnovation group and corporate tax executive with responsibility for the United States and Europe. Mr. Borgeson started his career as an auditor with Ernst & Young and is a certified public accountant inactive. He has an M.B.A. from R.I.T. and an undergraduate degree from the School of Management at the University at Buffalo (S.U.N.Y.).
- Hong Liang
Hong Liang是我们的高级副总裁，发现医学，自2015年12月以来一直担任该职位。梁博士在蛋白质治疗的研究与开发方面有20年的经验。在加入Kodiak之前，梁博士于2009年8月至2015年12月在辉瑞公司的Rinat实验室工作，职责越来越重，最近担任高级主任，通过3期临床开发专注于抗体生物制剂的设计和发现，以及转化生物标志物在药物开发中的应用。梁博士在斯坦福大学接受博士后培训，在西北大学获得博士学位，并在中国科学技术大学完成生物学要求。
Hong Liang is our Senior Vice President, Discovery Medicine and has served in this position since December 2015. Dr. Liang has 20 years of experience in research and development in protein therapeutics. Prior to joining Kodiak, Dr. Liang worked at the Rinat Laboratory of Pfizer Inc. in roles with increasing levels of responsibility from August 2009 to December 2015 most recently as Senior Director, focusing on antibody biologics design and discovery through Phase 3 clinical development as well the application of translational biomarkers to drug development. Dr. Liang trained as a postdoctoral fellow at Stanford University, earned a Ph.D. degree at Northwestern University, and completed requirements in Biology at the University of Science and Technology of China.- Hong Liang是我们的高级副总裁，发现医学，自2015年12月以来一直担任该职位。梁博士在蛋白质治疗的研究与开发方面有20年的经验。在加入Kodiak之前，梁博士于2009年8月至2015年12月在辉瑞公司的Rinat实验室工作，职责越来越重，最近担任高级主任，通过3期临床开发专注于抗体生物制剂的设计和发现，以及转化生物标志物在药物开发中的应用。梁博士在斯坦福大学接受博士后培训，在西北大学获得博士学位，并在中国科学技术大学完成生物学要求。
- Hong Liang is our Senior Vice President, Discovery Medicine and has served in this position since December 2015. Dr. Liang has 20 years of experience in research and development in protein therapeutics. Prior to joining Kodiak, Dr. Liang worked at the Rinat Laboratory of Pfizer Inc. in roles with increasing levels of responsibility from August 2009 to December 2015 most recently as Senior Director, focusing on antibody biologics design and discovery through Phase 3 clinical development as well the application of translational biomarkers to drug development. Dr. Liang trained as a postdoctoral fellow at Stanford University, earned a Ph.D. degree at Northwestern University, and completed requirements in Biology at the University of Science and Technology of China.